

Dick de Zeeuw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8825162/publications.pdf>

Version: 2024-02-01

567
papers

64,589
citations

1893

102
h-index

892

242
g-index

584
all docs

584
docs citations

584
times ranked

35299
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	3.8	13
2	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, 2022, 79, 244-256.e1.	1.9	23
3	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	2.9	5
4	Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 251-259.	4.5	19
5	Endothelin Receptor Antagonists for Kidney Protection. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 908-910.	4.5	10
6	Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC: Heart Failure, 2022, 10, 498-507.	4.1	4
7	Rationale, Design and Baseline Characteristics of the Effect of Canagliflozin in Type 2 Diabetic Patients with Microalbuminuria in Japanese Population (<i>CANPIONE</i>) study. Diabetes, Obesity and Metabolism, 2022, , .	4.4	1
8	<i>Sodium-glucose co-transporter 2</i> inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 382-390.	4.4	40
9	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases, 2021, 77, 23-34.e1.	1.9	38
10	New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney International, 2021, 99, 346-349.	5.2	42
11	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2021, 99, 999-1009.	5.2	93
12	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. Kidney International, 2021, 99, 551-554.	5.2	2
13	Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacology and Therapeutics, 2021, 109, 1631-1638.	4.7	5
14	Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the <i>SONAR</i> trial. Diabetes, Obesity and Metabolism, 2021, 23, 561-568.	4.4	10
15	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. CKJ: Clinical Kidney Journal, 2021, 14, 1396-1402.	2.9	18
16	A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882097419.	3.2	2
17	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	4.5	37
18	Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD. CKJ: Clinical Kidney Journal, 2021, 14, 2170-2176.	2.9	1

#	ARTICLE	IF	CITATIONS
19	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	2.7	30
20	Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program. Endocrinology, Diabetes and Metabolism, 2021, 4, e00247.	2.4	5
21	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1652-1659.	4.4	6
22	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
23	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	13.7	414
24	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. Stroke, 2021, 52, 1545-1556.	2.0	60
25	Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting. Frontiers in Pharmacology, 2021, 12, 662642.	3.5	1
26	129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial. Diabetes, 2021, 70, 129-LB.	0.6	0
27	133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE. Diabetes, 2021, 70, 133-LB.	0.6	0
28	131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial. Diabetes, 2021, 70, 131-LB.	0.6	0
29	Reasons for hospitalizations in patients with type 2 diabetes in the <scp>CANVAS</scp> programme: A secondary analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2707-2715.	4.4	6
30	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Post Hoc Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2731-2734.	6.1	6
31	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia, 2021, 64, 2402-2414.	6.3	6
32	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2900-2911.	6.1	9
33	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	13.7	133
34	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1824-1832.	4.5	11
35	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American Journal of Kidney Diseases, 2020, 75, 84-104.	1.9	311
36	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. JACC: Heart Failure, 2020, 8, 57-66.	4.1	93

#	ARTICLE	IF	CITATIONS
37	Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment. , 2020, , 211-224.		0
38	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. Circulation, 2020, 141, 407-410.	1.6	95
39	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes, Obesity and Metabolism, 2020, 22, 530-539.	4.4	14
40	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 2925-2936.	6.1	82
41	P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
42	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	5.2	65
43	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.	4.5	87
44	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2020, 31, 2446-2456.	6.1	15
45	The future of Diabetic Kidney Disease management: reducing the unmet need. Journal of Nephrology, 2020, 33, 1163-1169.	2.0	8
46	P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
47	P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
48	NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e017462.	3.7	34
49	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	6.1	106
50	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International, 2020, 98, 769-777.	5.2	69
51	EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL. Journal of the American College of Cardiology, 2020, 75, 215.	2.8	2
52	Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. Nephrology Dialysis Transplantation, 2020, 35, ii38-ii42.	0.7	10
53	Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol. BMC Nephrology, 2020, 21, 242.	1.8	22
54	Reply. JACC: Heart Failure, 2020, 8, 427.	4.1	0

#	ARTICLE	IF	CITATIONS
55	Atrasentan in patients with diabetes and chronic kidney disease – Authors' reply. Lancet, The, 2020, 395, 270.	13.7	1
56	Discontinuation of RAAS Inhibition in Children with Advanced CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 625-632.	4.5	19
57	27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. Diabetes, 2020, 69, .	0.6	2
58	2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes. Diabetes, 2020, 69, .	0.6	0
59	1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD). Diabetes, 2020, 69, .	0.6	0
60	1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial. Diabetes, 2020, 69, .	0.6	0
61	26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE. Diabetes, 2020, 69, .	0.6	0
62	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia, 2019, 62, 1854-1867.	6.3	58
63	Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin. Diabetes, Obesity and Metabolism, 2019, 21, 2635-2642.	4.4	1
64	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
65	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes, Obesity and Metabolism, 2019, 21, 2368-2383.	4.4	56
66	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	5.2	13
67	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2591-2593.	1.6	121
68	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia, 2019, 62, 926-938.	6.3	94
69	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	13.7	408
70	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	27.0	3,760
71	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2019, 30, 2229-2242.	6.1	93
72	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatology, The, 2019, 1, e220-e228.	3.9	38

#	ARTICLE	IF	CITATIONS
73	Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrology Dialysis Transplantation, 2019, 34, 1699-1706.	0.7	8
74	Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 66-73.	4.5	67
75	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke, 2019, 50, 396-404.	2.0	51
76	Future and Novel Compounds in the Treatment of Diabetic Nephropathy. , 2019, , 515-539.		3
77	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology, the, 2019, 7, 115-127.	11.4	199
78	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology, the, 2019, 7, 128-139.	11.4	223
79	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	1.9	49
80	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. Diabetes and Vascular Disease Research, 2019, 16, 47-56.	2.0	17
81	(Clinical) Trial and Error in Diabetic Nephropathy. , 2019, , 415-431.		0
82	1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program. Diabetes, 2019, 68, .	0.6	1
83	1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program. Diabetes, 2019, 68, .	0.6	0
84	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics. Kidney and Blood Pressure Research, 2018, 43, 181-190.	2.0	27
85	Determining the optimal dose of atrasentan by evaluating the exposure–response relationships of albuminuria and bodyweight. Diabetes, Obesity and Metabolism, 2018, 20, 2019-2022.	4.4	13
86	Baseline characteristics and enrichment results from the SONAR trial. Diabetes, Obesity and Metabolism, 2018, 20, 1829-1835.	4.4	28
87	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 2018, 20, 1369-1376.	4.4	60
88	Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 1377-1383.	4.4	10
89	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. European Heart Journal, 2018, 39, 1535-1542.	2.2	218
90	Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation, 2018, 138, 458-468.	1.6	370

#	ARTICLE	IF	CITATIONS
91	Does <scp>SGLT</scp>2 inhibition with dapagliflozin overcome individual therapy resistance to <scp>RAAS</scp> inhibition?. Diabetes, Obesity and Metabolism, 2018, 20, 224-227.	4.4	15
92	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia, 2018, 61, 581-588.	6.3	13
93	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	5.2	32
94	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. American Journal of Kidney Diseases, 2018, 71, 91-101.	1.9	57
95	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation, 2018, 137, 323-334.	1.6	393
96	Renal trials in diabetes need a platform: time for a global approach?. Lancet Diabetes and Endocrinology,the, 2018, 6, 356-358.	11.4	9
97	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 925-933.	11.4	30
98	Treating diabetic complications; from large randomized clinical trials to precision medicine. Diabetes, Obesity and Metabolism, 2018, 20, 3-5.	4.4	7
99	How to measure and monitor albuminuria in healthy toddlers?. PLoS ONE, 2018, 13, e0199309.	2.5	4
100	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation, 2018, 138, 1537-1550.	1.6	200
101	Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 2225-2233.	6.1	69
102	N-terminaal pro-Brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, Obesity and Metabolism, 2018, 20, 2899-2904.	4.4	10
103	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 691-704.	11.4	460
104	Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regions Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. Diabetes, 2018, 67, 1193-P.	0.6	1
105	Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. Diabetes, 2018, 67, 1191-P.	0.6	0
106	Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI). Diabetes, 2018, 67, .	0.6	0
107	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrology Dialysis Transplantation, 2017, 32, gfw292.	0.7	66
108	Systems Biology Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. Diabetes Care, 2017, 40, 391-397.	8.6	40

#	ARTICLE	IF	CITATIONS
109	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Studyâ€“Renal (<scp>CANVASâ€R</scp>): A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 387-393.	4.4	139
110	Optimizing the analysis strategy for the <scp>CANVAS</scp> Program: A prespecified plan for the integrated analyses of the <scp>CANVAS</scp> and <scp>CANVASâ€R</scp> trials. Diabetes, Obesity and Metabolism, 2017, 19, 926-935.	4.4	89
111	Comparison of exposure response relationship of atrasentan between <scp>N</scp>orth <scp>A</scp>merican and <scp>A</scp>sian populations. Diabetes, Obesity and Metabolism, 2017, 19, 545-552.	4.4	4
112	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	1.9	15
113	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 644-657.	27.0	5,629
114	The albuminuriaâ€lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes, Obesity and Metabolism, 2017, 19, 1363-1370.	4.4	88
115	Variability in response to albuminuriaâ€lowering drugs: true or random?. British Journal of Clinical Pharmacology, 2017, 83, 1197-1204.	2.4	22
116	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism, 2017, 19, 749-753.	4.4	19
117	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1804-1813.	4.5	7
118	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R and D, 2017, 17, 441-448.	2.2	6
119	Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1595-1600.	4.5	4
120	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	3.1	194
121	Is a reduction in albuminuria associated with renal and cardiovascular protection? A <i>post hoc</i> analysis of the <scp>ALTITUDE</scp> trial. Diabetes, Obesity and Metabolism, 2016, 18, 169-177.	4.4	49
122	Unmet need in diabetic nephropathy: failed drugs or trials?. Lancet Diabetes and Endocrinology,the, 2016, 4, 638-640.	11.4	40
123	Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats. American Journal of Physiology - Renal Physiology, 2016, 310, F1047-F1053.	2.7	5
124	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3405-3412.	6.1	8
125	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€”The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.8	1
126	Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a populationâ€based cohort study. ESC Heart Failure, 2016, 3, 189-197.	3.1	25

#	ARTICLE	IF	CITATIONS
127	Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 64-71.	4.4	59
128	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 82-91.	4.4	74
129	Novel anti-inflammatory drugs for the treatment of diabetic kidney disease. <i>Diabetologia</i> , 2016, 59, 1621-1623.	6.3	21
130	Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1351-1357.	2.4	10
131	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380.	1.9	57
132	Comparison of urine collection methods for albuminuria assessment in young children. <i>Clinica Chimica Acta</i> , 2016, 458, 120-123.	1.1	7
133	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 309-317.	11.4	39
134	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 758-768.	1.8	29
135	Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1471-1477.	0.7	16
136	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	1.9	19
137	Prevalence and distribution of (micro)albuminuria in toddlers. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1686-1692.	0.7	16
138	Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. <i>American Journal of Kidney Diseases</i> , 2016, 67, 70-78.	1.9	19
139	Renal end points in clinical trials of kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 1.	2.0	10
140	The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1245-1253.	2.4	22
141	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. <i>Journal of Hypertension</i> , 2015, 33, 2123-2132.	0.5	22
142	The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 678-686.	2.4	37
143	The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. <i>PLoS ONE</i> , 2015, 10, e0139755.	2.5	11
144	FP272A PANEL OF NOVEL BIOMARKERS REPRESENTING DIFFERENT DISEASE PATHWAYS IMPROVES PREDICTION OF RENAL FUNCTION DECLINE IN TYPE 2 DIABETES. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii158-iii158.	0.7	0

#	ARTICLE	IF	CITATIONS
145	Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1381-90.	2.3	9
146	Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 403-411.	8.6	196
147	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes and Endocrinology, 2015, 3, 181-190.	11.4	114
148	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection. Journal of the American Society of Nephrology: JASN, 2015, 26, 2055-2064.	6.1	204
149	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrology Dialysis Transplantation, 2015, 30, iv86-iv95.	0.7	33
150	Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension. Hypertension, 2015, 66, 563-570.	2.7	31
151	A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes. PLoS ONE, 2015, 10, e0120995.	2.5	57
152	Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td (No (Irbesartan Diabetic Nephropathy Trial)). American Journal of Kidney Diseases, 2015, 66, 450-458.	1.9	37
153	Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 410-416.	4.5	21
154	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes and Endocrinology, 2015, 3, 687-696.	11.4	221
155	The paradox created by commenting on large clinical trial results. Diabetes, Obesity and Metabolism, 2015, 17, 1-2.	4.4	0
156	The glycocalyx-linking albuminuria with renal and cardiovascular disease. Nature Reviews Nephrology, 2015, 11, 667-676.	9.6	128
157	Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2119-2127.	4.5	31
158	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy, 2015, 6, 289-302.	2.5	36
159	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1568-1574.	4.5	32
160	Albuminuria. , 2015, , 663-673.		2
161	Bilirubin and Progression of Nephropathy in Type 2 Diabetes: A Post Hoc Analysis of RENAAL With Independent Replication in IDNT. Diabetes, 2014, 63, 2845-2853.	0.6	57
162	The Authors Reply:. Kidney International, 2014, 86, 1270.	5.2	0

#	ARTICLE	IF	CITATIONS
163	Microalbuminuria: target for renoprotective therapy PRO. <i>Kidney International</i> , 2014, 86, 40-49.	5.2	65
164	New renal guidelines; is more better?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 720-721.	0.7	0
165	Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 64-74.	3.1	106
166	Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. <i>Kidney International</i> , 2014, 86, 819-827.	5.2	70
167	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 434-441.	1.8	19
168	GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. <i>American Journal of Kidney Diseases</i> , 2014, 64, 821-835.	1.9	430
169	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1825-1833.	6.1	142
170	Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 490-498.	4.5	24
171	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000011.	2.8	31
172	Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy. , 2014, , 222-234.		1
173	Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. <i>Journal of Psychosomatic Research</i> , 2014, 76, 134-138.	2.6	115
174	The effect of RAAS blockade on the progression of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2014, 10, 77-87.	9.6	128
175	A novel approach for establishing cardiovascular drug efficacy. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 942-942.	46.4	17
176	The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1083-1093.	6.1	222
177	Visit-to-Visit Variability in Blood Pressure and Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Nephropathy: A Post Hoc Analysis From the RENAAL Study and the Irbesartan Diabetic Nephropathy Trial. <i>American Journal of Kidney Diseases</i> , 2014, 64, 714-722.	1.9	65
178	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	1.7	139
179	The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 299-309.	1.8	36
180	Do diabetic kidneys deserve a lifestyle change?. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 769-770.	11.4	2

#	ARTICLE	IF	CITATIONS
181	Are Post-Trial Observational Studies Useful?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2148-2150.	6.1	2
182	Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study. Health and Quality of Life Outcomes, 2014, 12, 103.	2.4	11
183	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabetic Medicine, 2014, 31, 1138-1147.	2.3	119
184	Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). American Journal of Kidney Diseases, 2014, 63, 244-250.	1.9	55
185	The validity of a patient-reported adverse drug event questionnaire using different recall periods. Quality of Life Research, 2014, 23, 2439-2445.	3.1	8
186	Improving clinical trial efficiency by biomarker-guided patient selection. Trials, 2014, 15, 103.	1.6	16
187	The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers. Clinical Pharmacology and Therapeutics, 2014, 95, 208-215.	4.7	24
188	The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders. PLoS ONE, 2014, 9, e108722.	2.5	11
189	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). American Journal of Nephrology, 2013, 37, 212-222.	3.1	82
190	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial. American Heart Journal, 2013, 166, 217-223.e11.	2.7	290
191	The End of Dual Therapy with Renin-Angiotensin-Aldosterone System Blockade?. New England Journal of Medicine, 2013, 369, 1960-1962.	27.0	21
192	Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire. Drug Safety, 2013, 36, 765-777.	3.2	25
193	Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy. Diabetes Care, 2013, 36, 1489-1494.	8.6	33
194	LDL cholesterol in CKD—to treat or not to treat?. Kidney International, 2013, 84, 451-456.	5.2	49
195	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia, 2013, 56, 259-267.	6.3	128
196	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.	27.0	844
197	Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANIT cohort. Nephrology Dialysis Transplantation, 2013, 28, 706-715.	0.7	18
198	Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. Nephrology Dialysis Transplantation, 2013, 28, 2805-2815.	0.7	17

#	ARTICLE	IF	CITATIONS
199	PS3 - 5. Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 142-142.	0.0	0
200	PS11 - 1. Longitudinal eGFR trajectories in patients with type 2 diabetes. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 162-162.	0.0	0
201	Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database. BMJ Quality and Safety, 2013, 22, 339-347.	3.7	17
202	Dual RAAS blockade has dual effects on outcome. Nature Reviews Endocrinology, 2013, 9, 261-263.	9.6	4
203	Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2013, 15, 853-862.	4.4	658
204	Novel drugs and intervention strategies for the treatment of chronic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, 536-550.	2.4	38
205	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. Nephrology Dialysis Transplantation, 2013, 28, 2841-2850.	0.7	21
206	Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrology Dialysis Transplantation, 2013, 28, 2260-2268.	0.7	29
207	High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes. Journal of Hypertension, 2013, 31, 805-812.	0.5	19
208	Association Between Performance Measures and Glycemic Control Among Patients With Diabetes in a Community-wide Primary Care Cohort. Medical Care, 2013, 51, 172-179.	2.4	14
209	Predictors of Progression in Albuminuria in the General Population: Results from the PREVEND Cohort. PLoS ONE, 2013, 8, e61119.	2.5	20
210	Do Treatment Quality Indicators Predict Cardiovascular Outcomes in Patients with Diabetes?. PLoS ONE, 2013, 8, e78821.	2.5	13
211	PS12 - 60. Not all performance measures of diabetes management predict better glycemic control. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 140-141.	0.0	0
212	PS12 Contâ€™d - 62. Prescribing of aliskiren in practice: findings from the GIANTT diabetes. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 142-143.	0.0	0
213	Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nature Reviews Nephrology, 2012, 8, 691-699.	9.6	32
214	Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney International, 2012, 82, 330-337.	5.2	204
215	Comparison of Midregional Proâ€™A-Type Natriuretic Peptide and the N-Terminal Proâ€™B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events. Clinical Chemistry, 2012, 58, 293-297.	3.2	24
216	Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 123-130.	6.1	151

#	ARTICLE	IF	CITATIONS
217	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 387-393.	1.7	56
218	An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection. Journal of Hypertension, 2012, 30, 1022-1028.	0.5	24
219	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New England Journal of Medicine, 2012, 367, 2204-2213.	27.0	1,145
220	Albuminuria, Estimated GFR, Traditional Risk Factors, and Incident Cardiovascular Disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) Study. American Journal of Kidney Diseases, 2012, 60, 804-811.	1.9	79
221	Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart, 2012, 98, 1348-1353.	2.9	27
222	Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2340-2346.	8.6	52
223	Differential Effects of Comorbidity on Antihypertensive and Glucose-Regulating Treatment in Diabetes Mellitus â€” A Cohort Study. PLoS ONE, 2012, 7, e38707.	2.5	25
224	The Geographical Distribution of Leadership in Globalized Clinical Trials. PLoS ONE, 2012, 7, e45984.	2.5	31
225	Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency) Tj ETQq1 1 0.784314 rgBT / Overlock	1.4	11
226	Effect of Frozen Storage on Urinary Concentration of Kidney Damage Markers. American Journal of Kidney Diseases, 2012, 59, 586-589.	1.9	23
227	Validity of biomarkers predicting onset or progression of nephropathy in patients with Typeâ€f2 diabetes: a systematic review. Diabetic Medicine, 2012, 29, 567-577.	2.3	59
228	CKD Treatment: Time to Alter the Focus to Albuminuria?. Advances in Chronic Kidney Disease, 2011, 18, 222-223.	1.4	11
229	Comparing Adverse Event Rates of Oral Blood Glucose-Lowering Drugs Reported by Patients and Healthcare Providers. Drug Safety, 2011, 34, 1191-1202.	3.2	13
230	Omicsâ€”Bioinformatics in the Context of Clinical Data. Methods in Molecular Biology, 2011, 719, 479-497.	0.9	14
231	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	5.2	609
232	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney International, 2011, 80, 282-287.	5.2	282
233	Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). American Heart Journal, 2011, 162, 748-755.e3.	2.7	72
234	Paricalcitol for reduction of albuminuria in diabetes â€” Authors' reply. Lancet, The, 2011, 377, 636-637.	13.7	4

#	ARTICLE	IF	CITATIONS
235	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	13.7	2,087
236	A Longitudinal Study Examining Adherence to Guidelines in Diabetes Care According to Different Definitions of Adequacy and Timeliness. <i>PLoS ONE</i> , 2011, 6, e24278.	2.5	49
237	Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2011, 58, 729-736.	1.9	107
238	Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Diabetologia</i> , 2011, 54, 44-50.	6.3	91
239	High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçães AR, El Nahas AM [letter]. <i>Diabetologia</i> , 2011, 54, 2965-2967.	6.3	5
240	A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 83.	2.4	21
241	Gene therapy with adenovirus-delivered indoleamine 2,3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. <i>Journal of Gene Medicine</i> , 2011, 13, 373-381.	2.8	21
242	Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2011;34:703-709. <i>Diabetes Care</i> , 2011, 34, e124-124.	8.6	5
243	Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment. <i>Hypertension</i> , 2011, 58, 2-7.	2.7	164
244	Drug-Induced Changes in Risk/Biomarkers and Their Relationship with Renal and Cardiovascular Long-Term Outcome in Patients with Diabetes. <i>Clinical Chemistry</i> , 2011, 57, 186-195.	3.2	4
245	Initial Angiotensin Receptor Blockade-Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria. <i>Diabetes Care</i> , 2011, 34, 2078-2083.	8.6	58
246	Monitoring Kidney Function and Albuminuria in Patients With Diabetes. <i>Diabetes Care</i> , 2011, 34, S325-S329.	8.6	42
247	Unmet Need in Renal Protection – Do We Need a More Comprehensive Approach?. <i>Contributions To Nephrology</i> , 2011, 171, 157-160.	1.1	22
248	ROADMAP: the road to renoprotection?. <i>Nature Reviews Nephrology</i> , 2011, 7, 427-428.	9.6	0
249	ONTARGET still OFF-TARGET?. <i>Circulation</i> , 2011, 123, 1049-1051.	1.6	11
250	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. <i>European Heart Journal</i> , 2011, 32, 1493-1499.	2.2	115
251	Need for better diabetes treatment for improved renal outcome. <i>Kidney International</i> , 2011, 79, S28-S32.	5.2	48
252	Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review. <i>Medical Care Research and Review</i> , 2011, 68, 263-289.	2.1	93

#	ARTICLE	IF	CITATIONS
253	The Kidney in Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 392-402.	1.3	66
254	Rebuttal: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. American Journal of Nephrology, 2010, 31, 466-467.	3.1	10
255	Identifying targets to improve treatment in type 2 diabetes; the <i>Groningen Initiative to aNalyse Type 2 diabetes Treatment</i> (GIANTT) observational study. Pharmacoepidemiology and Drug Safety, 2010, 19, 1078-1086.	1.9	13
256	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 1146-1155.	27.0	433
257	Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy. Hypertension, 2010, 55, 1206-1209.	2.7	39
258	Comparison of Different Measures of Urinary Protein Excretion for Prediction of Renal Events. Journal of the American Society of Nephrology: JASN, 2010, 21, 1355-1360.	6.1	144
259	Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. American Journal of Physiology - Renal Physiology, 2010, 298, F625-F633.	2.7	29
260	N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. European Heart Journal, 2010, 31, 120-127.	2.2	103
261	Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. Nephrology Dialysis Transplantation, 2010, 25, 3560-3568.	0.7	16
262	Debate: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. American Journal of Nephrology, 2010, 31, 458-461.	3.1	35
263	Composite renal endpoints: was ACCOMPLISH accomplished?. Lancet, The, 2010, 375, 1140-1142.	13.7	38
264	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, The, 2010, 376, 1543-1551.	13.7	613
265	Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment. , 2010, , 105-116.		0
266	Screening for Albuminuria Identifies Individuals at Increased Renal Risk. Journal of the American Society of Nephrology: JASN, 2009, 20, 852-862.	6.1	133
267	Drug Dosing for Renoprotection. Journal of the American Society of Nephrology: JASN, 2009, 20, 688-689.	6.1	7
268	Reducing cardiovascular risk: protecting the kidney. European Heart Journal Supplements, 2009, 11, F39-F46.	0.1	2
269	Defining the optimal dose of a new drug: a crucial decision. Nature Reviews Nephrology, 2009, 5, 498-500.	9.6	6
270	First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria. Journal of the American Society of Nephrology: JASN, 2009, 20, 436-443.	6.1	225

#	ARTICLE	IF	CITATIONS
271	The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics. American Journal of Nephrology, 2009, 30, 280-286.	3.1	35
272	The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation, 2009, 24, 2975-2983.	0.7	11
273	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation, 2009, 24, 1663-1671.	0.7	286
274	High Protein Intake Associates with Cardiovascular Events but not with Loss of Renal Function. Journal of the American Society of Nephrology: JASN, 2009, 20, 1797-1804.	6.1	75
275	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2009, 54, 59-69.	1.9	60
276	Albuminuria: What can we expect from the determination of nonimmunoreactive albumin?. Current Hypertension Reports, 2009, 11, 111-117.	3.5	8
277	Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus. Diabetic Medicine, 2009, 26, 556-559.	2.3	17
278	Renal failure induces telomere shortening in the rat heart. Netherlands Heart Journal, 2009, 17, 190-194.	0.8	10
279	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.	27.0	2,110
280	Dual Renin-Angiotensin System Blockade and Kidney Disease. Journal of the American College of Cardiology, 2009, 54, 278-279.	2.8	11
281	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2009, 373, 1009-1015.	13.7	384
282	Albuminuria in heart failure: what do we really know?. Current Opinion in Cardiology, 2009, 24, 148-154.	1.8	20
283	Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension, 2009, 27, 2321-2331.	0.5	27
284	Does the European Clinical Trials Directive really improve clinical trial approval time?. British Journal of Clinical Pharmacology, 2008, 66, 546-550.	2.4	22
285	Is the randomized controlled drug trial in Europe lagging behind the USA?. British Journal of Clinical Pharmacology, 2008, 66, 774-780.	2.4	5
286	Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats. European Journal of Pharmacology, 2008, 580, 231-240.	3.5	6
287	Immune modulation and graft protection by gene therapy in kidney transplantation. European Journal of Pharmacology, 2008, 585, 261-269.	3.5	11
288	A Population-Based Screening for Microalbuminuria Among Relatives of CKD Patients: The Kidney Evaluation and Awareness Program in Sheffield (KEAPS). American Journal of Kidney Diseases, 2008, 52, 434-443.	1.9	24

#	ARTICLE	IF	CITATIONS
289	Targeting Proteinuria as a Valid Surrogate for Individualized Kidney Protective Therapy. American Journal of Kidney Diseases, 2008, 51, 713-716.	1.9	15
290	Extended Prognostic Value of Urinary Albumin Excretion for Cardiovascular Events. Journal of the American Society of Nephrology: JASN, 2008, 19, 1785-1791.	6.1	76
291	Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrology Dialysis Transplantation, 2008, 23, 3851-3858.	0.7	156
292	Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. Nephrology Dialysis Transplantation, 2008, 24, 413-420.	0.7	9
293	Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes. Diabetes Care, 2008, 31, S190-S193.	8.6	10
294	Impact of the Preintervention Rate of Renal Function Decline on Outcome of Renoprotective Intervention. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 54-60.	4.5	11
295	Albuminuria Assessed From First-Morning-Void Urine Samples Versus 24-Hour Urine Collections as a Predictor of Cardiovascular Morbidity and Mortality. American Journal of Epidemiology, 2008, 168, 897-905.	3.4	215
296	Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan. Journal of the American Society of Nephrology: JASN, 2008, 19, 999-1007.	6.1	330
297	ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy. Journal of the American Society of Nephrology: JASN, 2008, 19, 771-779.	6.1	80
298	Systemic gene therapy with interleukin-13 attenuates renal ischemiaâ€“reperfusion injury. Kidney International, 2008, 73, 1364-1373.	5.2	35
299	Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S10-S14.	3.3	18
300	Renal disease: a common and a silent killer. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S27-S35.	3.3	8
301	Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system. Kidney International, 2008, 74, 377-383.	5.2	11
302	Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. Nephrology Dialysis Transplantation, 2008, 24, 1182-1189.	0.7	28
303	Gender differences in predictors of the decline of renal function in the general population. Kidney International, 2008, 74, 505-512.	5.2	112
304	Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. Nephrology Dialysis Transplantation, 2008, 23, 3103-3110.	0.7	35
305	Prolonged Frozen Storage of Urine Reduces the Value of Albuminuria for Mortality Prediction. Clinical Chemistry, 2007, 53, 153-154.	3.2	25
306	Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 1540-1546.	6.1	280

#	ARTICLE	IF	CITATIONS
307	What Predicts Progression and Regression of Urinary Albumin Excretion in the Nondiabetic Population?. Journal of the American Society of Nephrology: JASN, 2007, 18, 637-645.	6.1	35
308	Urinary pH affects albumin concentrations after prolonged frozen storage. Nephrology Dialysis Transplantation, 2007, 22, 3670-3670.	0.7	10
309	Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation, 2007, 22, 1619-1627.	0.7	81
310	Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1959-1965.	6.1	154
311	Change in Albuminuria Is Predictive of Cardiovascular Outcome in Normotensive Patients With Type 2 Diabetes and Microalbuminuria. Diabetes Care, 2007, 30, 3119-3121.	8.6	25
312	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. Journal of Hypertension, 2007, 25, 871-876.	0.5	22
313	Claims in advertisements for antihypertensive drugs in a Dutch medical journal. Journal of Hypertension, 2007, 25, 713-722.	0.5	13
314	Apparent Loss of Urinary Albumin during Long-term Frozen Storage: HPLC vs Immunonephelometry. Clinical Chemistry, 2007, 53, 1520-1526.	3.2	41
315	Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy. Seminars in Nephrology, 2007, 27, 172-181.	1.6	65
316	Adenovirus-mediated interleukin-13 gene therapy attenuates acute kidney allograft injury. Journal of Gene Medicine, 2007, 9, 1024-1032.	2.8	17
317	Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study. Cardiovascular Diabetology, 2007, 6, 25.	6.8	20
318	Effect of First Myocardial Ischemic Event on Renal Function. American Journal of Cardiology, 2007, 100, 7-12.	1.6	37
319	Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy. Pharmacoeconomics, 2006, 24, 523-535.	3.3	22
320	Renoprotective effects of renin-angiotensin-system inhibitors. Lancet, The, 2006, 367, 899-900.	13.7	36
321	Microalbuminuria as an Early Marker for Cardiovascular Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2100-2105.	6.1	319
322	Gansevoort et al. Respond to "Using Measures of Albumin Excretion". American Journal of Epidemiology, 2006, 164, 731-732.	3.4	0
323	Microalbuminuria and Endothelial Dysfunction: Emerging Targets for Primary Prevention of End-organ Damage. Journal of Cardiovascular Pharmacology, 2006, 47, S151-S162.	1.9	95
324	The role of angiotensin(1-7) in renal vasculature of the rat. Journal of Hypertension, 2006, 24, 1971-1978.	0.5	42

#	ARTICLE	IF	CITATIONS
325	Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotaly nephrectomized rats. <i>Journal of Hypertension</i> , 2006, 24, 2215-2223.	0.5	27
326	Update on microalbuminuria as a biomarker in renal and cardiovascular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 631-636.	2.0	65
327	Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop. <i>Kidney International</i> , 2006, 69, 45-52.	5.2	13
328	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. <i>Kidney International</i> , 2006, 69, 1675-1682.	5.2	92
329	Physicians' attitudes towards treatment guidelines: differences between teaching and nonteaching hospitals. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 129-133.	1.9	14
330	Metabolic syndrome: a fata morgana?. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 15-20.	0.7	30
331	Endothelial Function Predicts the Development of Renal Damage after Combined Nephrectomy and Myocardial Infarction. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S49-S52.	6.1	15
332	Renoprotection by blocking the RAAS in diabetic nephropathy—fact or fiction?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2354-2357.	0.7	25
333	Potential role of active vitamin D in retarding the progression of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 321-328.	0.7	60
334	A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. <i>Current Medical Research and Opinion</i> , 2006, 22, 2095-2100.	1.9	7
335	Urinary Albumin Excretion as a Predictor of the Development of Hypertension in the General Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 331-335.	6.1	107
336	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 671-678.	1.6	817
337	Evaluation of Measures of Urinary Albumin Excretion. <i>American Journal of Epidemiology</i> , 2006, 164, 725-727.	3.4	54
338	Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 217-224.	1.7	12
339	Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2582-2590.	6.1	176
340	Renal Damage after Myocardial Infarction Is Prevented by Renin-Angiotensin-Aldosterone-System Intervention. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3059-3066.	6.1	26
341	Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 761-767.	4.5	171
342	Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. <i>Journal of Nephrology</i> , 2006, 19, 246-58.	2.0	37

#	ARTICLE	IF	CITATIONS
343	The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. <i>Journal of Hypertension</i> , 2005, 23, 2055-2061.	0.5	34
344	The association between atherosclerotic risk factors and renal function in the general population. <i>Kidney International</i> , 2005, 67, 1967-1973.	5.2	87
345	Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney International</i> , 2005, 67, 2089-2100.	5.2	2,836
346	Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. <i>Kidney International</i> , 2005, 67, S52-S54.	5.2	11
347	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. <i>Kidney International</i> , 2005, 67, S2-S7.	5.2	55
348	The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. <i>Kidney International</i> , 2005, 67, S28-S35.	5.2	132
349	Renoprotection with and without blood pressure reduction. <i>Kidney International</i> , 2005, 67, S54-S59.	5.2	16
350	Prevention of chronic kidney and vascular disease: Toward global health equityâ€”The Bellagio 2004 Declaration. <i>Kidney International</i> , 2005, 68, S1-S6.	5.2	86
351	The kidney, a cardiovascular risk marker, and a new target for therapy. <i>Kidney International</i> , 2005, 68, S25-S29.	5.2	95
352	Uptake of angiotensin II receptor blockers in the treatment of hypertension. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 461-466.	1.9	6
353	Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. <i>Diabetologia</i> , 2005, 48, 1980-1987.	6.3	41
354	Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk?. <i>Current Hypertension Reports</i> , 2005, 7, 379-384.	3.5	24
355	Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril. <i>European Journal of Heart Failure</i> , 2005, 7, 1085-1094.	7.1	4
356	Individual Titration for Maximal Blockade of the Renin-Angiotensin System in Proteinuric Patients: A Feasible Strategy?. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S53-S57.	6.1	26
357	Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1775-1780.	6.1	33
358	Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 2525-2530.	8.6	118
359	Letter Regarding Article by Klausen et al, â€œVery Low Levels of Microalbuminuria Are Associated With Increased Risk of Coronary Heart Disease and Death Independently of Renal Function, Hypertension, and Diabetesâ€. <i>Circulation</i> , 2005, 111, e110-1; author reply e110-1.	1.6	4
360	Albuminuria, Just a Marker for Cardiovascular Disease, Or Is It More?. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1883-1885.	6.1	18

#	ARTICLE	IF	CITATIONS
361	Does Angiotensin (1-7) Contribute to the Antiproteinuric Effect of ACE-inhibitors?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 96-101.	1.7	15
362	Falsely Low Urinary Albumin Concentrations after Prolonged Frozen Storage of Urine Samples. Clinical Chemistry, 2005, 51, 2181-2183.	3.2	59
363	Biochemical risk markers: a novel area for better prediction of renal risk?. Nephrology Dialysis Transplantation, 2005, 20, 497-508.	0.7	19
364	Renoprotective therapy: is it blood pressure or albuminuria that matters?. Lancet, The, 2005, 365, 913-914.	13.7	12
365	Rationaleâ€”Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 2005, 149, 408-413.	2.7	115
366	Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 552 T Hypertension, and Renal Disease. Diabetes Care, 2004, 27, 1897-1903.	8.6	91
367	Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 27-32.	1.7	10
368	Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. Circulation, 2004, 110, 2809-2816.	1.6	489
369	C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria. Hypertension, 2004, 43, 791-796.	2.7	84
370	Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 197-202.	1.7	11
371	Clinical Trial in Nephrology at Hard End Point?. Journal of the American Society of Nephrology: JASN, 2004, 15, 506-508.	6.1	9
372	Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results. Journal of the American Society of Nephrology: JASN, 2004, 15, 3117-3125.	6.1	112
373	Low Sodium Modifies the Vascular Effects of Angiotensin-Converting Enzyme Inhibitor Therapy in Healthy Rats. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1183-1189.	2.5	11
374	Myocardial Infarction Enhances Progressive Renal Damage in an Experimental Model for Cardio-Renal Interaction. Journal of the American Society of Nephrology: JASN, 2004, 15, 3103-3110.	6.1	78
375	The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. Journal of Internal Medicine, 2004, 256, 1-14.	6.0	289
376	Sodium intake affects urinary albumin excretion especially in overweight subjects. Journal of Internal Medicine, 2004, 256, 324-330.	6.0	187
377	Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International, 2004, 65, 1416-1421.	5.2	836
378	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International, 2004, 65, 2309-2320.	5.2	842

#	ARTICLE	IF	CITATIONS
379	Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. <i>Kidney International</i> , 2004, 66, S2-S6.	5.2	78
380	Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future?. <i>Kidney International</i> , 2004, 66, S7-S10.	5.2	36
381	An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. <i>Kidney International</i> , 2004, 66, S18-S21.	5.2	155
382	Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. <i>Kidney International</i> , 2004, 66, S69-S75.	5.2	63
383	Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease. <i>Kidney International</i> , 2004, 66, S97-S98.	5.2	3
384	Approaches and methods in gene therapy for kidney disease. <i>Journal of Pharmacological and Toxicological Methods</i> , 2004, 50, 13-24.	0.7	24
385	Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. <i>Circulation</i> , 2004, 110, 921-927.	1.6	679
386	C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. <i>Atherosclerosis</i> , 2004, 172, 107-114.	0.8	48
387	Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. <i>American Heart Journal</i> , 2004, 148, 165-172.	2.7	57
388	Should albuminuria be a therapeutic target in patients with hypertension and diabetes?. <i>American Journal of Hypertension</i> , 2004, 17, S11-S15.	2.0	17
389	Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study. <i>Journal of Hypertension</i> , 2004, 22, 1033-1037.	0.5	24
390	Does comorbidity explain trends in prescribing of newer antihypertensive agents?. <i>Journal of Hypertension</i> , 2004, 22, 2209-2215.	0.5	13
391	The Abnormal Renal Vasodilator Response to D1-Like Receptor Stimulation in Conscious SHR Can Be Normalized by AT1 Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 571-576.	1.9	6
392	Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II. <i>Journal of Hypertension</i> , 2004, 22, 2355-2361.	0.5	29
393	Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1316-22.	6.1	48
394	A central body fat distribution is related to renal function impairment, even in lean subjects. <i>American Journal of Kidney Diseases</i> , 2003, 41, 733-741.	1.9	309
395	The reliability of different formulae to predict creatinine clearance. <i>Journal of Internal Medicine</i> , 2003, 253, 563-573.	6.0	55
396	Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. <i>Kidney International</i> , 2003, 63, 64-71.	5.2	17

#	ARTICLE	IF	CITATIONS
397	C-reactive protein is associated with renal function abnormalities in a non-diabetic population. <i>Kidney International</i> , 2003, 63, 654-661.	5.2	208
398	The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. <i>Kidney International</i> , 2003, 63, 1499-1507.	5.2	456
399	Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT ₁ receptor blockade. <i>British Journal of Pharmacology</i> , 2003, 139, 1317-1325.	5.4	43
400	CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA. <i>Value in Health</i> , 2003, 6, 615-616.	0.3	0
401	The COOPERATE trial. <i>Lancet</i> , The, 2003, 361, 1055-1056.	13.7	7
402	Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. <i>Annals of Internal Medicine</i> , 2003, 139, 244.	3.9	945
403	Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 106-112.	1.7	15
404	Role of the Endothelin-1 Gene Locus for Renal Impairment in the General Nondiabetic Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2596-2602.	6.1	25
405	Cardiovascular Risk Factors Are Differently Associated with Urinary Albumin Excretion in Men and Women. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1330-1335.	6.1	110
406	Coronary Myogenic Constriction Antagonizes EDHF-Mediated Dilation. <i>Hypertension</i> , 2003, 41, 912-918.	2.7	19
407	Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1543-1550.	1.8	3
408	Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2003, 139, 90.	3.9	60
409	Role of proteinuria in the regulation of renal renin-angiotensin system components in unilateral proteinuric rats. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 38-42.	1.7	4
410	Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure. <i>European Journal of Heart Failure</i> , 2003, 5, 147-154.	7.1	21
411	High Dietary Sodium Blunts Effects of Angiotensin-converting Enzyme Inhibition on Vascular Angiotensin II Conversion in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, 601-606.	1.9	24
412	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2047-2053.	0.7	143
413	Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 10-13.	0.7	88
414	Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat. <i>Clinical Science</i> , 2003, 105, 51-57.	4.3	2

#	ARTICLE	IF	CITATIONS
415	Best practice of hypertensive patients with kidney disease. British Journal of Hospital Medicine, 2003, 64, 96-100.	0.2	0
416	Best practice for hypertensive patients with kidney disease. British Journal of Hospital Medicine, 2003, 64, 96-100.	0.2	0
417	Renoprotection: A Matter of Blood Pressure Reduction or Agent-Characteristics?. Journal of the American Society of Nephrology: JASN, 2002, 13, S202-S207.	6.1	14
418	D2-Like Receptor Stimulation Decreases Effective Renal Plasma Flow and Glomerular Filtration Rate in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2002, 40, 35-42.	1.9	2
419	Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 205-213.	1.7	32
420	Targeting of Captopril to the Kidney Reduces Renal Angiotensin-Converting Enzyme Activity without Affecting Systemic Blood Pressure. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 1139-1143.	2.5	11
421	Endothelial Dilatory Function Predicts Individual Susceptibility to Renal Damage in the 5/6 Nephrectomized Rat. Journal of the American Society of Nephrology: JASN, 2002, 13, 2909-2915.	6.1	53
422	Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population. Circulation, 2002, 106, 1777-1782.	1.6	1,395
423	Statins. Journal of Hypertension, 2002, 20, 2351-2353.	0.5	1
424	Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability. Current Opinion in Nephrology and Hypertension, 2002, 11, 135-140.	2.0	9
425	Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?. Nephrology Dialysis Transplantation, 2002, 17, 793-797.	0.7	3
426	Targeting of Doxorubicin to the Urinary Bladder of the Rat Shows Increased Cytotoxicity in the Bladder Urine Combined With An Absence of Renal Toxicity. Journal of Drug Targeting, 2002, 10, 81-89.	4.4	15
427	Normalization of aortic function during arousal episodes in the hibernating ground squirrel. Life Sciences, 2002, 70, 2071-2083.	4.3	12
428	How to measure the prevalence of microalbuminuria in relation to age and gender?. American Journal of Kidney Diseases, 2002, 40, 436-437.	1.9	11
429	Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney International, 2002, 61, 473-480.	5.2	24
430	Can angiotensin II be used for renoprotection?. Kidney International, 2002, 61, 1176-1177.	5.2	2
431	Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney International, 2002, 62, 181-191.	5.2	37
432	Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney International, 2002, 62, 1020-1025.	5.2	152

#	ARTICLE	IF	CITATIONS
433	The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review. British Journal of Clinical Pharmacology, 2002, 53, 549P-550P.	2.4	5
434	Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats. British Journal of Pharmacology, 2002, 136, 1107-1116.	5.4	10
435	Specific drug delivery to the kidney. Cardiovascular Drugs and Therapy, 2002, 16, 489-496.	2.6	44
436	Enhanced Responses of Blood Pressure, Renal Function, and Aldosterone to Angiotensin I in the DD Genotype Are Blunted by Low Sodium Intake. Journal of the American Society of Nephrology: JASN, 2002, 13, 1025-1033.	6.1	61
437	How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria. , 2002, , 69-73.		0
438	How to measure the prevalence of microalbuminuria in relation to age and gender?. American Journal of Kidney Diseases, 2002, 40, 436-7; author reply 437.	1.9	5
439	Renal function as a predictor of prognosis in chronic heart failure. Heart Failure Monitor, 2002, 2, 78-84.	0.7	4
440	Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Annals of Internal Medicine, 2001, 135, 73.	3.9	927
441	Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2001, 345, 861-869.	27.0	6,609
442	Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. American Journal of Kidney Diseases, 2001, 38, 1381-1384.	1.9	46
443	Intracellular angiotensin II inhibits heterologous receptor stimulated Ca ²⁺ entry. Life Sciences, 2001, 70, 171-180.	4.3	7
444	POTENTIALS AND LIMITATIONS OF THE LOW-MOLECULAR-WEIGHT PROTEIN LYSOZYME AS A CARRIER FOR RENAL DRUG TARGETING. Renal Failure, 2001, 23, 397-409.	2.1	29
445	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney International, 2001, 60, 1131-1140.	5.2	334
446	Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. Journal of Internal Medicine, 2001, 249, 519-526.	6.0	547
447	Intracellular Angiotensin II and cell growth of vascular smooth muscle cells. British Journal of Pharmacology, 2001, 132, 1590-1596.	5.4	40
448	Intracellular angiotensin II elicits Ca ²⁺ increases in A7r5 vascular smooth muscle cells. European Journal of Pharmacology, 2001, 420, 9-18.	3.5	18
449	Does a low-salt diet exert a protective effect on endothelial function in normal rats?. Translational Research, 2001, 138, 200-205.	2.3	7
450	Excessive Urinary Albumin Levels Are Associated With Future Cardiovascular Mortality in Postmenopausal Women. Circulation, 2001, 103, 3057-3061.	1.6	135

#	ARTICLE	IF	CITATIONS
451	Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 771-775.	0.7	41
452	Review: Intracellular angiotensin II: from myth to reality?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 219-226.	1.7	21
453	Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease. <i>Seminars in Nephrology</i> , 2001, 21, 580-592.	1.6	12
454	Smoking Is Related to Albuminuria and Abnormal Renal Function in Nondiabetic Persons. <i>Annals of Internal Medicine</i> , 2000, 133, 585.	3.9	229
455	Renal hemodynamics in human hypertension. <i>Advances in Organ Biology</i> , 2000, 9, 369-382.	0.1	2
456	The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 57-61.	2.0	14
457	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International</i> , 2000, 57, S32-S37.	5.2	37
458	Letters. <i>Diabetic Medicine</i> , 2000, 17, 550-552.	2.3	10
459	Comparison of zofenopril and lisinopril to study the role of the sulfhydryl group in improvement of endothelial dysfunction with ACE inhibitors in experimental heart failure. <i>British Journal of Pharmacology</i> , 2000, 130, 1999-2007.	5.4	63
460	ACE Inhibition Preserves Heparan Sulfate Proteoglycans in the Glomerular Basement Membrane of Rats with Established Adriamycin Nephropathy. <i>Nephron Experimental Nephrology</i> , 2000, 9, 21-27.	2.2	31
461	Low Levels of Urinary Albumin Excretion Are Associated with Cardiovascular Risk Factors in the General Population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 1107-10.	2.3	46
462	Renal Function, Neurohormonal Activation, and Survival in Patients With Chronic Heart Failure. <i>Circulation</i> , 2000, 102, 203-210.	1.6	935
463	The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 328-335.	1.7	118
464	Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats. <i>Journal of the Autonomic Nervous System</i> , 2000, 78, 117-121.	1.9	10
465	Chronic beta-blocker treatment in patients with advanced heart failure. <i>International Journal of Cardiology</i> , 2000, 73, 7-12.	1.7	31
466	Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable?. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 256-262.	0.6	37
467	Regulation of [Ca ²⁺] _i homeostasis in MRP1 overexpressing cells. <i>FEBS Letters</i> , 2000, 474, 107-110.	2.8	10
468	Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 637-643.	0.7	37

#	ARTICLE	IF	CITATIONS
469	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International</i> , 2000, 57, 32-37.	5.2	3
470	Direct Vasodilating Effects of the New Dopaminergic Agonist Z1046 in Human Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 581-585.	1.9	5
471	LONG-TERM RENAL OUTCOME AFTER LUNG TRANSPLANTATION IS PREDICTED BY THE 1-MONTH POSTOPERATIVE RENAL FUNCTION LOSS. <i>Transplantation</i> , 2000, 69, 1624-1628.	1.0	56
472	Urinary Albumin Excretion Is Associated with Renal Functional Abnormalities in a Nondiabetic Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1882-1888.	6.1	276
473	Chronic Angiotensin II Infusion But Not Bradykinin Blockade Abolishes the Antiproteinuric Response to Angiotensin-Converting Enzyme Inhibition in Established Adriamycin Nephrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 490-496.	6.1	17
474	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters. , 2000, , 587-600.		1
475	Renin Inhibition Improves Pressure Natriuresis in Essential Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1813-1818.	6.1	11
476	Angiotensin-(1â€“7) Is a Modulator of the Human Renin-Angiotensin System. <i>Hypertension</i> , 1999, 34, 296-301.	2.7	164
477	Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. <i>European Journal of Clinical Investigation</i> , 1999, 29, 1019-1026.	3.4	6
478	Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. <i>Kidney International</i> , 1999, 56, S42-S46.	5.2	5
479	Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta. <i>British Journal of Pharmacology</i> , 1999, 126, 1133-1138.	5.4	25
480	Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. <i>European Journal of Clinical Pharmacology</i> , 1999, 54, 953-958.	1.9	21
481	Angiotensin-converting enzyme gene I/D polymorphism and renal disease. <i>Journal of Molecular Medicine</i> , 1999, 77, 781-791.	3.9	27
482	Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. <i>Journal of Pharmacological and Toxicological Methods</i> , 1999, 41, 69-73.	0.7	28
483	Renoprotective therapy: titration against urinary protein excretion. <i>Lancet, The</i> , 1999, 354, 352-353.	13.7	102
484	Angiotensin-converting enzyme gene I/D polymorphism and renal disease. , 1999, 77, 781.		1
485	Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. <i>Kidney International</i> , 1999, 56, 42-46.	5.2	8
486	Impaired Renal Vascular Response to a D1-Like Receptor Agonist But Not to an ACE Inhibitor in Conscious Spontaneously Hypertensive Rats. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 34, 191-198.	1.9	21

#	ARTICLE	IF	CITATIONS
487	Systemic Factors Are Involved in the Pathogenesis of Proteinuria-Induced Glomerulosclerosis in Adriamycin Nephrotic Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 2359-2366.	6.1	35
488	A comparison of analytic procedures for measurement of fractional dextran clearances. <i>Translational Research</i> , 1998, 132, 390-403.	2.3	21
489	Sample Dilution: A Methodological Pitfall in the Measurement of Tissue but not Serum Ace-Activity. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998, 39, 45-49.	0.7	9
490	Can Continuous Intraperitoneal Infusion of 125 I-Iothalamate and 131 I-Hippuran Be Used for Measurement of GFR in Conscious Rats?. <i>Renal Failure</i> , 1998, 20, 249-255.	2.1	1
491	Drug Delivery to the Kidneys and the Bladder with the Low Molecular Weight Protein Lysozyme. <i>Renal Failure</i> , 1998, 20, 211-217.	2.1	21
492	Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat. <i>Clinical Science</i> , 1998, 95, 603-609.	4.3	13
493	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters. , 1998, , 585-595.		1
494	Proteinuria and progression of renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 133-140.	2.0	30
495	δ^9 -Tetrahydrocannabinol activates $[Ca^{2+}]_i$ increases partly sensitive to capacitative store refilling. <i>European Journal of Pharmacology</i> , 1997, 336, R1-R3.	3.5	35
496	ACE-inhibitors: panacea for progressive renal disease?. <i>Lancet, The</i> , 1997, 349, 1852-1853.	13.7	38
497	A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. <i>Kidney International</i> , 1997, 51, 793-797.	5.2	180
498	A method for accurate measurement of GFR in conscious, spontaneously voiding rats. <i>Kidney International</i> , 1997, 52, 244-247.	5.2	16
499	Drug-targeting to the kidney: Renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. <i>Kidney International</i> , 1997, 52, 1693-1699.	5.2	56
500	Urine collection in the freely moving rat: Reliability for measurement of short-term renal effects. <i>Journal of Pharmacological and Toxicological Methods</i> , 1997, 38, 47-51.	0.7	15
501	Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. <i>Biomedical Applications</i> , 1997, 693, 181-189.	1.7	49
502	Determination of dopaminergic prodrugs by high-performance liquid chromatography followed by post-column ion-pair extraction. <i>Biomedical Applications</i> , 1997, 693, 484-488.	1.7	1
503	Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. <i>Lancet, The</i> , 1996, 347, 94-95.	13.7	163
504	The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 723-730.	3.4	10

#	ARTICLE	IF	CITATIONS
505	ACE Inhibitors and the Kidney. Drug Safety, 1996, 15, 200-211.	3.2	70
506	Antiproteinuric Effect Predicts Renal Protection by Angiotensin-Converting Enzyme Inhibition in Rats with Established Adriamycin Nephrosis. Clinical Science, 1996, 90, 393-401.	4.3	68
507	(Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting. Journal of Controlled Release, 1996, 39, 163-172.	9.9	21
508	Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney International, 1996, 49, 174-180.	5.2	11
509	Proteinuria. Obstetrical and Gynecological Survey, 1996, 51, 145-146.	0.4	1
510	Does the Renin-Angiotensin System Determine the Renal and Systemic Hemodynamic Response to Sodium in Patients With Essential Hypertension?. Hypertension, 1996, 27, 202-208.	2.7	58
511	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters. , 1996, , 551-559.		0
512	Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. Journal of Hypertension, 1995, 13, S53-S58.	0.5	23
513	Renal and Systemic Effects of the Renin Inhibitor Remikiren in Patients with Essential Hypertension. Journal of Cardiovascular Pharmacology, 1995, 26, 39-45.	1.9	15
514	Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrology Dialysis Transplantation, 1995, 10, 497-504.	0.7	161
515	Drug-induced changes in renal hippurate clearance as a measure of renal blood flow. Kidney International, 1995, 48, 1617-1623.	5.2	8
516	Proteinuria: A risk factor for pregnancy-related renal function decline in primary glomerular disease?. American Journal of Kidney Diseases, 1995, 26, 187-192.	1.9	12
517	Drug targeting to the kidney with low-molecular-weight proteins. Advanced Drug Delivery Reviews, 1994, 14, 67-88.	13.7	25
518	Discordant effects of enalapril and lisinopril on systemic and renal hemodynamics. Clinical Pharmacology and Therapeutics, 1994, 56, 647-658.	4.7	11
519	Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. Kidney International, 1994, 45, 861-867.	5.2	264
520	A general method for the determination of the kinetic stability of macrocyclic alkali-metal complexes with rates of decomplexation below 10^{-3} s $^{-1}$. Journal of the Chemical Society Perkin Transactions II, 1994, , 11-14.	0.9	3
521	Functionalized Calixspherands: Synthesis and Peptide Coupling. Journal of Organic Chemistry, 1994, 59, 972-976.	3.2	20
522	Kinetically stable complexes of alkali cations with calixspherands: an evaluation of shielding. Journal of the American Chemical Society, 1994, 116, 123-133.	13.7	57

#	ARTICLE	IF	CITATIONS
523	Quantification of renal low-molecular-weight protein handling in the intact rat. <i>Kidney International</i> , 1993, 43, 949-954.	5.2	32
524	Role of elevated lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. <i>Kidney International</i> , 1993, 44, 91-97.	5.2	60
525	Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. <i>Kidney International</i> , 1993, 44, 579-584.	5.2	59
526	Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid. <i>Pharmaceutical Research</i> , 1993, 10, 963-969.	3.5	31
527	Have Rational Therapeutic Principles Emerged in Treating Hypertension in Chronic Renal Failure?. <i>American Journal of Kidney Diseases</i> , 1993, 21, 108-112.	1.9	0
528	Long-Term Benefits of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition in Nondiabetic Renal Disease. <i>American Journal of Kidney Diseases</i> , 1993, 22, 202-206.	1.9	99
529	Quantification of Renal Low-Molecular-Weight Protein Degradation in the Intact Rat. <i>Contributions To Nephrology</i> , 1993, 101, 78-84.	1.1	4
530	The Antiproteinuric Effects of Blood Pressure-Lowering Agents: Differences Between Nondiabetics and Diabetics. <i>Journal of Cardiovascular Pharmacology</i> , 1992, 19, S28-S32.	1.9	7
531	Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension.. <i>Hypertension</i> , 1992, 20, 80-84.	2.7	8
532	Management of chronic renal failure. <i>Current Opinion in Nephrology and Hypertension</i> , 1992, 1, 116-123.	2.0	0
533	Accelerated progression of renal function loss after two pregnancies in a patient with proteinuria. <i>Lancet, The</i> , 1992, 340, 183.	13.7	1
534	Low-molecular-weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 1246-1259.	6.4	61
535	Differences in erythrocyte sodium transport between human plasma and artificial medium: the role and character of sodium efflux and influx stimulating plasma factors. <i>Clinica Chimica Acta</i> , 1992, 213, 61-73.	1.1	1
536	Influence of Anaesthesia on Renal Hippurate Handling during Angiotensin-Converting Enzyme Inhibition in Unilateral Renal Artery Stenosis. <i>American Journal of Nephrology</i> , 1992, 12, 474-476.	3.1	1
537	Atrial natriuretic factor: Its (patho)physiological significance in humans. <i>Kidney International</i> , 1992, 41, 1115-1133.	5.2	95
538	Renal specific delivery of sulfamethoxazole in the rat by coupling to the low molecular weight protein lysozyme via an acid-sensitive linker. <i>International Journal of Pharmaceutics</i> , 1992, 80, R15-R19.	5.2	17
539	Clearance of indometacin occurs predominantly by renal glucuronidation. <i>Pharmaceutisch Weekblad</i> , 1992, 14, 191-195.	0.7	9
540	Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: A clue to the mechanism of action. <i>Clinical Science</i> , 1991, 81, 367-372.	4.3	23

#	ARTICLE	IF	CITATIONS
541	Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. Pharmaceutical Research, 1991, 08, 1223-1230.	3.5	47
542	Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. Kidney International, 1991, 40, 734-741.	5.2	49
543	The Antiproteinuric Effect of Angiotensin-Converting-Enzyme Inhibitors in Human Renal Disease. , 1991, , 95-113.		8
544	Relief of Renal Artery Stenosis: A Tool to Improve or Preserve Renal Function in Renovascular Disease?. Nephrology Dialysis Transplantation, 1990, 5, 481-488.	0.7	11
545	Mechanism of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition1. Contributions To Nephrology, 1990, 83, 160-165.	1.1	8
546	Unilateral Renal Parenchymal Disease with Contralateral Renal Artery Stenosis of the Fibrodysplasia Type. Annals of Internal Medicine, 1989, 110, 437.	3.9	10
547	Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney International, 1989, 36, 272-279.	5.2	332
548	Human plasma contains low molecular weight factors which stimulate active sodium transport in erythrocytes. Clinica Chimica Acta, 1989, 179, 133-142.	1.1	1
549	Angiotensin Converting Enzyme Inhibitors and Progressive Renal Insufficiency. Annals of Internal Medicine, 1989, 111, 503.	3.9	141
550	Atrial Natriuretic Peptide-Induced Decreases in Renal Blood Flow in Man: Implications for the Natriuretic Mechanism. Clinical Science, 1989, 77, 55-60.	4.3	17
551	A new constrictor device for external induction of a long-term stable and irreversible renal artery stenosis in the dog. Pflugers Archiv European Journal of Physiology, 1988, 411, 688-691.	2.8	1
552	Micro-HPLC and transfer techniques for directly measuring drug (indomethacin) transport across the isolated perfused renal proximal straight tubule. Journal of Pharmacological Methods, 1988, 19, 275-282.	0.7	1
553	Angiotensin converting enzyme inhibition improves diagnostic procedures for renovascular hypertension in dogs.. Hypertension, 1988, 12, 411-419.	2.7	18
554	Angiotensin converting enzyme inhibition induces alterations to hippuran renography despite unchanged ipsilateral renal blood flow in conscious two-kidney, one clip Goldblatt hypertensive dogs. Journal of Hypertension, 1988, 6, S455-457.	0.5	3
555	Indomethacin secretion in the isolated perfused proximal straight rabbit tubule. Evidence for two parallel transport mechanisms.. Journal of Clinical Investigation, 1988, 81, 1585-1592.	8.2	5
556	Diuretic Effects of Angiotensin-Converting Enzyme Inhibition. Journal of Cardiovascular Pharmacology, 1987, 9, 743-748.	1.9	51
557	Preorganized macrocyclic ligands: a novel approach to functionalized hemispherands via aromatization. Journal of Organic Chemistry, 1987, 52, 4913-4921.	3.2	32
558	Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney International, 1987, 32, 78-83.	5.2	201

#	ARTICLE	IF	CITATIONS
559	Moderate sodium restriction in hypertensive subjects: Renal effects of ACE-inhibition. <i>Kidney International</i> , 1987, 31, 815-819.	5.2	58
560	Effects of nonsteroidal anti-inflammatory drugs on proteinuria. <i>American Journal of Medicine</i> , 1986, 81, 84-94.	1.5	77
561	Highly sensitive measurement of indomethacin using a high-performance liquid chromatographic technique combined with post-column in-line hydrolysis. <i>Biomedical Applications</i> , 1986, 380, 157-162.	1.7	16
562	Antiproteinuric Effect of Naproxen and Indomethacin. <i>American Journal of Nephrology</i> , 1985, 5, 236-242.	3.1	33
563	Blood pressure response to enalaprilic acid in essential hypertension: Dose-response and effect of pre-treatment with furosemide. <i>European Journal of Clinical Pharmacology</i> , 1985, 29, 9-15.	1.9	7
564	Pharmacological zero for electromagnetic renal blood flow measurement. <i>Pflugers Archiv European Journal of Physiology</i> , 1985, 403, 220-221.	2.8	5
565	Semi-micro method for the determination of cation flux rate constants in erythrocytes. <i>Clinica Chimica Acta</i> , 1985, 150, 137-149.	1.1	3
566	Nephroptosis and Kidney Function. <i>Nephron</i> , 1978, 22, 366-373.	1.8	13
567	Unilateral Kidney Blood Flow Measurement Using the $^{81}\text{Rb}/^{81}\text{mKr}$ Ratio. <i>Contributions To Nephrology</i> , 1978, 11, 67-72.	1.1	3